Elicio Therapeutics, Inc.股价上涨11.00% 市值跌156.67万美元

市场透视12-17

北京时间2024年12月17日23时43分，Elicio Therapeutics, Inc.（ELTX.us）股票出现异动，股价大幅上涨11.00%。截至发稿，该股报5.45美元/股，成交量6758股，换手率0.06%，振幅7.54%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-18.84百万美元，每股收益-1.39美元，毛利-290000.00美元，市盈率-1.38倍。机构评级...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492077961?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-17 23:43","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2492077961","market":"us","top_or_hot":-1,"title":"Elicio Therapeutics, Inc.股价上涨11.00% 市值跌156.67万美元","media":"市场透视","content":"<div>\n<p>北京时间2024年12月17日23时43分，Elicio Therapeutics, Inc.（ELTX.us）股票出现异动，股价大幅上涨11.00%。截至发稿，该股报5.45美元/股，成交量6758股，换手率0.06%，振幅7.54%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-18.84百万美元，每股收益-1.39美元，毛利-290000.00美元，市盈率-1.38倍。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121723431495ea33b2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elicio Therapeutics, Inc.股价上涨11.00% 市值跌156.67万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElicio Therapeutics, Inc.股价上涨11.00% 市值跌156.67万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 23:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121723431495ea33b2&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2024年12月17日23时43分，Elicio Therapeutics, Inc.（ELTX.us）股票出现异动，股价大幅上涨11.00%。截至发稿，该股报5.45美元/股，成交量6758股，换手率0.06%，振幅7.54%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-18.84百万美元，每股收益-1.39美元，毛利-290000.00美元，市盈率-1.38倍。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121723431495ea33b2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELTX","symbol_name":"Elicio Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121723431495ea33b2&s=b","article_id":"2492077961","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121723431495ea33b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492077961","pubTimestamp":1734450194,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2024年12月17日23时43分，Elicio Therapeutics, Inc.股票出现异动，股价大幅上涨11.00%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ELTX":"Elicio Therapeutics","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Elicio Therapeutics, Inc. Shares Rise 11.00%, Market Value Down $1,566,700","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELTX":1,"LENZ":1},"content_text":"北京时间2024年12月17日23时43分，Elicio Therapeutics, Inc.（ELTX.us）股票出现异动，股价大幅上涨11.00%。截至发稿，该股报5.45美元/股，成交量6758股，换手率0.06%，振幅7.54%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-18.84百万美元，每股收益-1.39美元，毛利-290000.00美元，市盈率-1.38倍。机构评级方面，在所有2家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Portage Biotech Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 (To Pur Com)、Celularity Inc C/Wts 16/07/2026 (To Pur Com)涨幅较大，Portage Biotech Inc.、Tonix Pharmaceuticals Holding Corp.、Polyrizon Ltd.较为活跃，换手率分别为1788.41%、259.03%、114.27%，振幅较大的相关个股有Tonix Pharmaceuticals Holding Corp.、Klotho Neurosciences Inc C/Wts 21/06/2029 (To Pur Com)、Portage Biotech Inc.，振幅分别为137.26%、95.10%、78.77%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。 其专有的 Amphiphile（AMP）平台将研究中的免疫治疗药物直接输送到免疫系统的大脑中心和淋巴结。 其重点是针对经过生物学验证但难以药物治疗的靶点开发癌症免疫疗法，这些靶点可通过淋巴结运输激活。 Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。 该公司已经开发了其癌症疫苗候选产品，以使用已知的新抗原来针对经过生物学验证的肿瘤突变驱动因素。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492077961"}